GALMED PHARMACEUTICALS LTD. Payments to Acquire Marketable Securities
GALMED PHARMACEUTICALS LTD. (GLMD) reported Payments to Acquire Marketable Securities of $1.44 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-03-31
| Period end | Payments to Acquire Marketable Securities 12 month |
|---|---|
| 2025-12-31 | $1.44M 20-F · filed 2026-03-31 |
| 2024-12-31 | $5.12M 20-F · filed 2026-03-31 |
| 2023-12-31 | $4.13M 20-F · filed 2026-03-31 |